Clinical Trials
3 trialsNCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02450903 2021-03-30
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Novartis
Phase 2 Completed
NCT01685138 2019-03-26
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Novartis
Phase 2 Completed